Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Gains from Sales and Divestitures (2021 - 2025)

Medicinova (MNOV) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures changed N/A to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.1 million for FY2025, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $1.1 million at Medicinova, up from $970000.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.2 million in Q4 2021, with the low at $9000.0 in Q3 2024.
  • Average Gains from Sales and Divestitures over 4 years is $856033.3, with a median of $970000.0 recorded in 2025.
  • The sharpest move saw Gains from Sales and Divestitures crashed 98.77% in 2024, then surged 10677.78% in 2025.
  • Over 4 years, Gains from Sales and Divestitures stood at $1.2 million in 2021, then tumbled by 38.42% to $730350.0 in 2023, then plummeted by 98.77% to $9000.0 in 2024, then soared by 11788.89% to $1.1 million in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $1.1 million, $970000.0, and $970000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.